GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer
NCT04979663
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
10
Enrollment
OTHER
Sponsor class
Conditions
Biliary Tract Carcinoma
Interventions
COMBINATION_PRODUCT:
Combination of Gemcitabine, Oxaliplatin, Donafenib and Tislelizumab
Sponsor
Fudan University